Q1 26 EPS
$2.70
Q1 26 Revenue
$24.06B
BEAT +1.89%
Est. $23.61B
vs S&P Since Q1 26
-8.6%
TRAILING MARKET
JNJ -4.8% vs S&P +3.8%
Market Reaction
Did JNJ Beat Earnings? Q1 2026 Results
Johnson & Johnson opened 2026 on solid footing, posting first-quarter revenue of $24.06 billion, up 9.9% year-over-year and ahead of the $23.61 billion consensus estimate, while adjusted EPS of $2.70 edged past the $2.68 analyst expectation by 0.85%,… Read more Johnson & Johnson opened 2026 on solid footing, posting first-quarter revenue of $24.06 billion, up 9.9% year-over-year and ahead of the $23.61 billion consensus estimate, while adjusted EPS of $2.70 edged past the $2.68 analyst expectation by 0.85%, extending the company's streak of consensus EPS beats to four consecutive quarters. The primary engine behind the top-line strength was the Innovative Medicine segment, where oncology delivered standout performance led by DARZALEX at $3.96 billion and CARVYKTI surging 62.1% to $597 million, more than offsetting a sharp 59.7% decline in STELARA as biosimilar competition intensified. MedTech contributed $8.64 billion, with Cardiovascular climbing 13.0% to $2.38 billion. Separately, the Board approved a 3.1% dividend increase to $1.34 per share quarterly, marking 64 consecutive years of dividend growth. Looking ahead, management raised its full-year 2026 guidance, now targeting revenue of $100.30 billion to $101.30 billion and adjusted diluted EPS of $11.45 to $11.65, reinforcing confidence in its path toward double-digit growth by decade's end.
Key Takeaways
- • DARZALEX worldwide sales grew 22.5% to $3,964M driven by strong demand
- • TREMFYA surged 68.3% to $1,608M as it captures share from biosimilar-eroded STELARA
- • CARVYKTI grew 62.1% to $597M reflecting expanding cell therapy adoption
- • RYBREVANT/LAZCLUZE grew 82.7% to $257M on new indication approvals
- • CAPLYTA contributed $270M following Intra-Cellular Therapies acquisition in April 2025
- • Electrophysiology, Abiomed, and Shockwave drove MedTech Cardiovascular growth of 13.0%
- • Trauma products drove Orthopaedics growth in MedTech
- • STELARA biosimilar competition resulted in 59.7% decline to $656M, approximately 920 bps drag on Innovative Medicine
- • Favorable currency translation contributed 3.5% to worldwide sales growth
JNJ Forward Guidance & Outlook
Johnson & Johnson raised its full-year 2026 guidance. The company now expects estimated reported sales of $100.3B–$101.3B (midpoint $100.8B, 7.0% growth at midpoint), up from the prior January guidance of $100.0B–$101.0B (midpoint $100.5B). Adjusted operational sales growth is now expected at 5.6%–6.6% (midpoint 6.1%), up from 5.4%–6.4% (midpoint 5.9%). Adjusted EPS (diluted) is guided at $11.45–$11.65 (midpoint $11.55, 7.1% growth at midpoint), up from $11.43–$11.63 (midpoint $11.53). Adjusted operational EPS (diluted) is guided at $11.30–$11.50 (midpoint $11.40, 5.7% growth at midpoint). The company is solidifying its path to double-digit growth by the end of the decade. An Enterprise Business Review is planned for December 8, 2026.
JNJ YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
JNJ Revenue by Segment
With YoY comparisons, source: SEC Filings
JNJ Revenue by Geography
With YoY comparisons, source: SEC Filings
“Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact.”
— Joaquin Duato, Q1 2026 Earnings Press Release
JNJ Earnings Trends
JNJ vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
JNJ EPS Trend
Earnings per share: estimate vs actual
JNJ Revenue Trend
Quarterly revenue: estimate vs actual
JNJ Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.70 | — | $24.06B | +1.89% |
| Q4 25 BEAT FY | $2.46 | $2.46 | +0.00% | $24.56B | — |
| FY Full Year | $10.80 | $10.79 | -0.13% | $94.19B | +0.46% |
| Q3 25 BEAT | $2.76 | $2.80 | +1.49% | $23.99B | +1.00% |
| Q2 25 BEAT | $2.68 | $2.77 | +3.43% | $23.74B | +3.88% |
| Q1 25 BEAT | $2.58 | $2.77 | +7.34% | $21.89B | +1.48% |